Core Viewpoint - The legal opinion letter from Changshi Law Firm confirms that the 2025 Second Extraordinary General Meeting of Tianjin Pharmaceutical Co., Ltd. was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association [1][8]. Group 1: Meeting Procedures - The meeting was convened based on a resolution from the 17th meeting of the 9th Board of Directors held on June 25, 2025, and the notice was published on June 26, 2025 [3][4]. - The meeting was held on July 15, 2025, at the specified location, and the actual time and place matched the notice [4][6]. - A network voting platform was provided for shareholders, allowing them to vote during specified times [4][7]. Group 2: Attendance and Qualifications - A total of 8 shareholders and their proxies attended the meeting, representing 9,243,482 shares, which is 0.8466% of the total voting shares [4][5]. - Additionally, 293 shareholders participated via the network voting system, representing 36,877,352 shares, or 3.3377% of the total voting shares [5]. - The qualifications of all attendees, including the convenor, were verified to be in compliance with relevant laws and the company's articles of association [5][6]. Group 3: Voting Results - The first agenda item regarding the mortgage application for a loan by a controlling subsidiary was approved with 43,376,634 votes in favor (94.0499%), 1,999,800 votes against (4.3360%), and 744,400 abstentions (1.6141%) [6][8]. - The voting procedures and results were confirmed to be valid and in accordance with legal requirements and the company's articles of association [8].

天津市河西区宾水道 11 号宾泰公寓 C-1801 电话：022-28363638 传真：022-28363638 长实律师事务所 ChangshiLaw Firm 天津长实律师事务所 关于津药药业股份有限公司 2025 年 第二次临时股东大会的 法律意见书 长实律见字【2025】55号 天津长实律师事务所 天津长实律师事务所 关于津药药业股份有限公司2025年第二次临时股东大会的 法律意见书 长实律见字【2025】55号 致：津药药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》等法律、法规和规范性文件以及《津药 药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，天津长实 律师事务所（以下简称"本所"）接受津药药业股份有限公司（以下简称"贵公 司"）委托，指派律师出席了贵公司召开的2025年第二次临时股东大会（以下简 称"本次股东大会"）现场会议，并就本次股东大会相关事宜出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，并查阅了贵公司提供的有关召开本次股东大会相关文件的原件或影印件， ...

证券代码：600488 证券简称：津药药业 公告编号：2025-043 津药药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 301 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 46,120,834 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 4.2239 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长徐华先生主持，采取现场记名 投票和网络投票相结合的表决方式。会议召集、召开程序符合《中华人民共和国 公司法》《公司章程》等的规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席8人，逐一说明未出席董事及其理由 ...

Core Viewpoint - The company, Tianyao Pharmaceutical Co., Ltd., anticipates a significant decline in net profit for the first half of 2025, projecting a decrease of 62.19% to 68.38% compared to the same period last year [1][2]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of approximately 44.9 million to 53.7 million yuan for the first half of 2025, a decrease of 88.32 million to 97.12 million yuan year-on-year [1][2]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be around 112 million to 121 million yuan, reflecting a year-on-year decrease of 18.59 million to 19.59 million yuan [1][2]. Group 2: Previous Year Performance - For the same period last year, the net profit attributable to shareholders was 142.02 million yuan [2]. - The basic earnings per share for the previous year were reported at 0.130 yuan [2]. Group 3: Reasons for Profit Decline - The decline in profit is attributed to the impact of the tenth batch of centralized procurement, which led to a decrease in the unit price of selected products, thereby reducing revenue and gross profit [2]. - The raw material pharmaceutical business faced intensified market competition, resulting in decreased sales volume and unit prices for certain products, further impacting revenue and profit [2].

第九届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第十 八次会议于 2025 年 7 月 11 日以通讯表决的方式召开。本次会议的通 知已于 2025 年 7 月 2 日以电子邮件的方式送达公司各位董事、监事 和高管人员。会议应参加表决董事 9 人，实际表决董事 9 人。会议符 合《公司法》和《公司章程》的有关规定，决议如下： 1.审议通过关于聘任公司副总经理的议案 经总经理李书箱先生提名，公司薪酬与提名委员会审议通过，聘 任陈洪先生为公司副总经理。陈洪先生简历如下： 证券代码：600488 证券简称：津药药业 编号：2025-041 津药药业股份有限公司 陈洪，男，1970 年出生，南京医科大学医学学士，长江商学院 EMBA 硕士。历任广州白云山和记黄埔中药有限公司常务副总经理，国 药控股和记黄埔医药（上海）有限公司总经理兼法人代表，和黄健宝 保健品有限公司总经理，广州和黄汉优有机产品有限公司总经理，和 黄医药高级副总裁、执行副总裁、首 ...

[Key Highlights](index=1&type=section&id=Key%20Highlights) The company anticipates a significant decline of 62.19% to 68.38% in net profit attributable to shareholders for the 2025 semi-annual period, with non-recurring net profit expected to decrease by 13.32% to 19.77% - This performance forecast applies to situations where profitability is achieved, but net profit has decreased by over 50% compared to the same period last year[3](index=3&type=chunk) 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | [Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) This section details the performance forecast for January 1 to June 30, 2025, indicating a year-on-year decline in both net profit attributable to shareholders and non-recurring net profit, with the forecast being unaudited - The performance forecast period is from January 1, 2025, to June 30, 2025[4](index=4&type=chunk) 2025 Semi-Annual Performance Forecast | Metric | 2025 Semi-Annual Forecast (10,000 CNY) | Year-on-Year Change (10,000 CNY) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 4,490 - 5,370 | Decrease 8,832.02 - 9,712.02 | Decrease 62.19% - 68.38% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 11,200 - 12,100 | Decrease 1,859.05 - 2,759.05 | Decrease 13.32% - 19.77% | - The performance forecast presented herein is unaudited[4](index=4&type=chunk) [Prior Period Performance](index=1&type=section&id=Item%202.%20Prior%20Period%20Performance) This section presents the net profit attributable to shareholders, non-recurring net profit, and basic earnings per share for the 2024 semi-annual period, serving as the comparative baseline for the current forecast 2024 Semi-Annual Actual Performance | Metric | 2024 Semi-Annual Actual (10,000 CNY) | | :--- | :--- | | Net Profit Attributable to Shareholders | 14,202.02 | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 13,959.05 | | Basic Earnings Per Share | 0.130 CNY | [Main Reasons for Performance Decline](index=2&type=section&id=Item%203.%20Main%20Reasons%20for%20Performance%20Decline) The anticipated performance decline is primarily due to multiple factors including centralized procurement, intensified international market competition, and administrative fines for monopolistic behavior, leading to a year-on-year decrease in sales revenue and profit - The company's sales revenue and profit experienced a certain degree of year-on-year decline this year, influenced by factors such as centralized procurement and intensified international market competition[7](index=7&type=chunk) - The pharmaceutical preparation business saw a year-on-year decrease in revenue and gross profit due to the impact of the tenth batch of centralized procurement, which led to a decline in the unit price of winning bid products[7](index=7&type=chunk) - The active pharmaceutical ingredient (API) business experienced a year-on-year decline in revenue and profit, as both sales volume and unit prices of some products decreased due to intensified market competition[7](index=7&type=chunk) - The company incurred an administrative fine of **69.1924 million CNY** this year due to monopolistic behavior[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=Item%204.%20Risk%20Warning) The company declares that there are no significant uncertainties affecting the accuracy of this performance forecast - There are no significant uncertainties affecting the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanatory Notes](index=2&type=section&id=Item%205.%20Other%20Explanatory%20Notes) Investors are reminded that the forecast data is preliminary, and final financial figures will be based on the officially disclosed semi-annual report, with a caution regarding investment risks - The aforementioned forecast data represents preliminary calculations by the company's finance department[9](index=9&type=chunk) - Should there be a significant discrepancy between the disclosed performance forecast and actual results, the company will promptly issue a revised performance forecast announcement[9](index=9&type=chunk) - The specific and accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[9](index=9&type=chunk)

津药药业（600488）公告，预计2025年半年度实现归属于上市公司股东的净利润约为4490万元到5370万 元，与上年同期相比将减少8832.02万元到9712.02万元，同比减少62.19%到68.38%。公司预计2025年半 年度实现归属于上市公司股东的扣除非经常性损益的净利润约为1.12亿元到1.21亿元，与上年同期相比 将减少1859.05万元到2759.05万元，同比减少13.32%到19.77%。 ...

津药药业股份有限公司 津药药业股份有限公司 会议资料 津药药业股份有限公司 $$\langle\exists\exists\exists\exists\exists\forall\exists\exists\exists\exists\exists\exists$$ 津药药业 2025 年第二次临时股东大会会议议案之一 关于控股子公司以自有资产抵押申请贷款 暨关联交易的议案 (已经 2025 年 6 月 25 日第九届董事会第 17 次会议审议通过) 一、关联交易概述 （一）本次交易的基本情况 津药药业股份有限公司(以下简称"公司")于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次 临时股东大会审议通过"关于公司与天津医药集团财务有限公司关联 交易的议案"，公司与天津医药集团财务有限公司（以下简称"财务 公司" ）签订《金融服务协议》，财务公司向公司提供金融服务总额不 超过 12.03 亿元（详见公司公告 2023-086#）。 公司于 2024 年 6 月 17 日经第九届董事会第八次会议与公司第九 届监事会第六次会议审议通过"关于控股子公司 ...

会议资料 2025 年 7 月 津药药业股份有限公司 2025 年第二次临时股东大会 津药药业股份有限公司 2025 年第二次临时股东大会 2 / 7 津药药业股份有限公司 2025 年第二次临时股东大会 津药药业 2025 年第二次临时股东大会会议议案之一 1 / 7 津药药业股份有限公司 2025 年第二次临时股东大会 目录 1.关于控股子公司以自有资产抵押申请贷款暨关联交易的议案 ............ 3 关于控股子公司以自有资产抵押申请贷款 暨关联交易的议案 (已经 2025 年 6 月 25 日第九届董事会第 17 次会议审议通过) 一、关联交易概述 （一）本次交易的基本情况 津药药业股份有限公司(以下简称"公司")于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次 临时股东大会审议通过"关于公司与天津医药集团财务有限公司关联 交易的议案"，公司与天津医药集团财务有限公司（以下简称"财务 公司"）签订《金融服务协议》，财务公司向公司提供金融服务总额不 超过 12.03 亿元（详见公司公告 2023-086#）。 公司于 2024 年 ...

Core Viewpoint - The cosmetics industry in Shandong Province is entering a phase of high-quality development, but it faces unprecedented challenges. The industry must leverage technology and brand strength to reshape its landscape and achieve sustainable growth [2][9]. Group 1: Industry Development and Challenges - The 2025 Northern Beauty Valley Conference highlighted the need for deep integration of production, education, research, and application to promote high-quality development in the cosmetics industry [3][28]. - The industry is experiencing significant growth, with the output value increasing from 20 billion to 30 billion from 2022 to 2024, driven by the Northern Beauty Valley initiative [28]. Group 2: Technological Innovations - Technological innovation is identified as the core driving force for high-quality development in the cosmetics industry [6][9]. - Breakthroughs in synthetic biology, such as the development of royal jelly acid, are paving the way for innovative raw materials in cosmetics [11]. - The introduction of transdermal absorption technology has significantly improved the efficiency of active ingredients in cosmetics [15]. Group 3: Cultural and Brand Strategies - The integration of traditional Chinese medicine with modern molecular biology is providing innovative solutions for effective cosmetic development [17]. - Shandong beauty companies are adopting a "cultural empowerment + digital marketing" strategy to enhance brand competitiveness [21][24]. - The brand "Yilian" achieved a revenue of 250 million in the first quarter of 2025, reflecting a 25% year-on-year growth, driven by its dual strategy of technology and culture [24]. Group 4: Collaborative Efforts and Future Directions - The Northern Beauty Valley is fostering collaboration among government, enterprises, universities, and research institutions to create a resource-sharing ecosystem [28][29]. - The establishment of a high-end think tank with 80 expert members aims to support technological advancements in the cosmetics industry [28][29]. - The Shandong Cosmetics Association is compiling a directory of unique cosmetic raw materials to enhance innovation and support the industry's development [19].